CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases.

The distinction between small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and mantle cell lymphoma (MCL) has important clinical implications. Typically, SLL/CLL is CD23+, whereas MCL is CD23-. However, CD23 is expressed in a subset of MCLs, and the clinicopathologic features of patients with these neoplasms are not well described. We report 18 CD23+ MCLs, detected by flow cytometry in all cases (dim intensity, 16; bright intensity, 2), 5 (28%), also positive by immunohistochemical analysis. There were 13 men and 5 women (median age, 56 years), 5 of whom died (median survival, 46 months). Seventeen (94%) had bone marrow involvement. Lymphadenopathy (14 cases [78%]), splenomegaly (11 cases [61%]), and leukemic involvement (10 cases [56%]) were common. Five cases (28%) had blastoid morphologic features. The frequency of CD23 expression by MCL is method-dependent, being typically dim and most commonly detected by flow cytometry. In this small study group, bone marrow and leukemic involvement were relatively common.

[1]  M. Sarfati.  CD23 and chronic lymphocytic leukemia. , 1993, Blood cells.

[2]  N. Piva,et al.  Atypical chronic lymphocytic leukaemia witht(ll;14)(ql3;q32): karyotype evolution and prolymphocytic transformation , 1995, British journal of haematology.

[3]  S. Miyawaki,et al.  Quantitative analysis of Cyclin D1 and CD23 expression in mantle cell lymphoma and B-chronic lymphocytic leukemia. , 2002, Leukemia research.

[4]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[5]  C. Ross,et al.  Leukemic phase of mantle cell lymphoma, blastoid variant. , 1999, American journal of clinical pathology.

[6]  Paul J. Kurtin,et al.  Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. , 1999, American journal of clinical pathology.

[7]  S. Perkins,et al.  Mantle Cell Leukemia, Prolymphocytoid Type: a Rarely Described Form , 2001, Leukemia & lymphoma.

[8]  S. Pittaluga,et al.  Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. , 1996, Leukemia & lymphoma.

[9]  S. Alkan,et al.  Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[10]  J. Tworek,et al.  Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. , 1998, American journal of clinical pathology.

[11]  A. Lagoo,et al.  Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2001, American journal of clinical pathology.

[12]  G. Salles,et al.  Mantle cell lymphoma: a retrospective study of 121 cases , 1998, Leukemia.

[13]  L. Medeiros,et al.  Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases , 2001, Modern Pathology.

[14]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[15]  S. Pittaluga,et al.  Mantle cell lymphoma: a clinicopathological study of 55 cases , 1995, Histopathology.

[16]  T. Molina,et al.  Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome , 2000, Virchows Archiv.

[17]  J. Jackson,et al.  Low‐molecular weight B cell growth factor (BCGF‐12KD) as an autocrine growth factor in B cell chronic lymphocytic leukemia , 1992, European journal of immunology.

[18]  L. Medeiros,et al.  Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. , 2001, American journal of clinical pathology.

[19]  S. Perkins,et al.  CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic transformations of mantle cell lymphoma. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  A. Rosenwald,et al.  The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. , 1998, Leukemia & lymphoma.

[21]  B. Branger,et al.  Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype , 2001, Leukemia.

[22]  H. Nielsen,et al.  Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. , 1991 .

[23]  N. Harris,et al.  Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. , 1993, American journal of clinical pathology.

[24]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.

[25]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gascoyne,et al.  Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma , 2000, Modern Pathology.

[27]  G. Inghirami,et al.  Large‐cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome , 1996, British journal of haematology.

[28]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[29]  M. N. Kilo,et al.  The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. , 1996, American journal of clinical pathology.

[30]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[31]  E. Jaffe,et al.  Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  J. So,et al.  Mantle cell lymphoma in leukemic phase , 1999, Cancer.

[33]  W. Chan,et al.  Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group , 2000, American journal of hematology.

[34]  J. Cawley,et al.  Heterogeneity of CLL: high CD23 antigen and αIFN receptor expression are features of favourable disease and of cell activation , 1988, British journal of haematology.

[35]  G. Pinkus,et al.  Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[36]  P. Cohen,et al.  Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.

[37]  J. Chan,et al.  Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. , 2002, American journal of clinical pathology.

[38]  M. Rooney,et al.  Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. , 2001, American journal of clinical pathology.